Figure 1.
Association between changes in UACR during the 6-weeks response-enrichment period and subsequent kidney outcomes recorded during the double-blind treatment period. (A) The association in participants who continued atrasentan during the double-blind treatment period. (B) The association in participants who transitioned from atrasentan to placebo at randomization.